Kiniksa Pharmaceuticals International, plc
KNSA
株式のランク
#2868
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
株価
$83.13
最終同期: 2026-10-20
時価総額
$6.49B
変化（1日）
4.59%
変化（1年）
113.97%
国
GB
取引 Kiniksa Pharmaceuticals International, plc (KNSA)
カテゴリー
Healthcare
Kiniksa Pharmaceuticals International, plc（KNSA）の収益
Jun 2026 時点の収益 TTM: $840.85M
Kiniksa Pharmaceuticals International, plc の最新の財務報告によると、現在の収益 (TTM) は $840.85M です。2023 年には $270.26M の収益があり、これは 2022 年の $220.18M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Kiniksa Pharmaceuticals International, plc の収益履歴（2016 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $840.85M | 98.67% |
| 2024 | $423.24M | 56.60% |
| 2023 | $270.26M | 22.74% |
| 2022 | $220.18M | 471.24% |
| 2021 | $38.54M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $2.54B | 201.60% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | -1.19% |
US
|
